According to the survey of Rocco et al. [13] in Europe and North America, as well as the data of the ADJUVANT/CTONG1104 study in China [14], there are large treatment strategy differences for IIIA-N2 locally advanced non-small-cell lung cancer. Certainly, in patients in whom surgery may be indicated for IIIA-N2, surgery should follow preoperative chemotherapy for oncologic reasons [15], and delay the surgery beyond the window of the pandemic. Patients who might be considered marginal candidates for surgery might be treated with chemoradiation followed by immunotherapy, according to the PACIFIC trial [16], avoiding the risks of hospitalization during the pandemic without compromising treatment for cure. There was no statistically significant difference in overall survival between chemoradiotherapy alone versus chemoradiotherapy plus surgery [17]. As well, during the COVID-19 pandemic, clinicians should rely to a greater extent on positron emission tomography for staging [18], to replace invasive biopsies and reduce the chance of infection among medical workers.